vimarsana.com

Page 130 - நாஸ்டாக் உலகளாவிய தேர்ந்தெடுக்கவும் சந்தை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Karolinska Development AB (publ): Karolinska Development s portfolio company Aprea Therapeutics receives orphan drug designation for eprenetapopt in AML

(0) STOCKHOLM, SWEDEN - April 9, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Aprea Therapeutics drug candidate eprenetapopt for the treatment of acute myeloid leukemia (AML). KDev Investments, a company jointly owned by Karolinska Development and Rosetta Capital, holds 8 percent of the shares in Aprea Therapeutics, which is listed on Nasdaq Global Select Market in the USA. Eprenetapopt is a small molecule targeting the tumor suppressor protein p53. Mutations of the p53 gene occur in around 50% of all human tumors and are associated with poor overall survival.

NANOBIOTIX Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F

NANOBIOTIX Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

Eastern Bankshares, Inc and Century Bancorp, Inc Enter Into Definitive Agreement To Merge

Press release content from Business Wire. The AP news staff was not involved in its creation. Eastern Bankshares, Inc. and Century Bancorp, Inc. Enter Into Definitive Agreement To Merge April 8, 2021 GMT BOSTON & MEDFORD, Mass. (BUSINESS WIRE) Apr 7, 2021 Eastern Bankshares, Inc. (“Eastern”) (Nasdaq Global Select Market: EBC), the stock holding company for Eastern Bank, and Century Bancorp, Inc. (Nasdaq: CNBKA) (“Century”), the stock holding company for Century Bank and Trust Company (“Century Bank”), today jointly announced they have entered into a definitive all-cash merger agreement with an aggregate transaction value of $642 million. This in-market transaction comes less than six months after Eastern’s initial public offering that raised approximately $1.7 billion in equity capital.

NANOBIOTIX Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 2

PARIS & CAMBRIDGE, Mass. (BUSINESS WIRE) Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘ Company’’) , a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the filing of its universal registration document for the financial year ended December 31, 2020 with the French financial market authority ( Autorité des marchés financiers or AMF), as well as its annual report on Form 20-F for the financial year ended December 31, 2020 with the U.S. Securities and Exchange Commission (SEC). These documents are available on Nanobiotix’s website at https://www.nanobiotix.com/regulated-information/. In addition, the 2020 universal registration document is available on the AMF website (www.amf-france.org) and the 2020 Annual Report on Form 20-F is available on the SEC website (www.sec.gov).

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.